{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320826618112.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1872-034x.2007.00292.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2007.00292.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1872-034X.2007.00292.x"}},{"identifier":{"@type":"PMID","@value":"18034827"}}],"dc:title":[{"@value":"Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p><jats:bold>Aim: </jats:bold> Lamivudine (LAM) has been widely used to treat chronic hepatitis B (CHB) patients, but the emergence of a LAM‐resistant virus greatly limits its therapeutic efficacy. In this study, we tried to identify factors affecting the emergence of a LAM‐resistant virus in CHB patients treated with LAM.</jats:p><jats:p><jats:bold>Methods: </jats:bold> The subjects were 190 CHB patients in continuous LAM therapy (139 males, mean age 50 years, 87 HBeAg‐positive). The mean duration of follow‐up was 39 months (range 12–104). The initial viral response (IVR) was defined as HBV DNA < 4.0 logcopies/mL, and the initial biochemical response (IBR) as normalization of alanine aminotransferase (ALT) (<40 IU/L) at 6 months.</jats:p><jats:p><jats:bold>Results: </jats:bold> IVR was positive in 86% of the patients. The cumulative emergence rates of LAM‐resistant virus were 10% at 1 year, 30% at 2 years and 46% at 3 years. In univariate analysis, factors contributing to the emergence of LAM‐resistant virus were baseline HBV DNA > 6.5 logcopies/mL (<jats:italic>P</jats:italic> = 0.0044), HBeAg‐positivity (<jats:italic>P</jats:italic> = 0.0062), IBR (<jats:italic>P</jats:italic> = 0.01) and IVR (<jats:italic>P</jats:italic> < 0.0001). The cumulative emergence rates of LAM‐resistant virus in IVR‐positive and ‐negative patients were 4% and 41% at 1 year, and 41% and 79% at 3 years. In multivariate analysis, only IVR was an independent factor affecting the emergence of LAM‐resistant virus (<jats:italic>P</jats:italic> < 0.0001).</jats:p><jats:p><jats:bold>Conclusion: </jats:bold> IVR is a useful factor for predicting the emergence of LAM‐resistant virus in CHB patients treated with LAM. For IVR‐negative patients, therapeutic options other than LAM monotherapy should be used because of the high incidence of the emergence of LAM‐resistant virus.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320826617987","@type":"Researcher","foaf:name":[{"@value":"Nao Kurashige"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617984","@type":"Researcher","foaf:name":[{"@value":"Naoki Hiramatsu"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617999","@type":"Researcher","foaf:name":[{"@value":"Kazuyoshi Ohkawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617988","@type":"Researcher","foaf:name":[{"@value":"Tsugiko Oze"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826618115","@type":"Researcher","foaf:name":[{"@value":"Yuko Inoue"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617996","@type":"Researcher","foaf:name":[{"@value":"Mika Kurokawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617998","@type":"Researcher","foaf:name":[{"@value":"Takayuki Yakushijin"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617991","@type":"Researcher","foaf:name":[{"@value":"Takumi Igura"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826618116","@type":"Researcher","foaf:name":[{"@value":"Shinichi Kiso"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617990","@type":"Researcher","foaf:name":[{"@value":"Tatsuya Kanto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826618113","@type":"Researcher","foaf:name":[{"@value":"Tetsuo Takehara"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617994","@type":"Researcher","foaf:name":[{"@value":"Shinji Tamura"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617997","@type":"Researcher","foaf:name":[{"@value":"Akinori Kasahara"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617985","@type":"Researcher","foaf:name":[{"@value":"Masahide Oshita"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617992","@type":"Researcher","foaf:name":[{"@value":"Taizo Hijioka"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617989","@type":"Researcher","foaf:name":[{"@value":"Kazuhiro Katayama"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826618112","@type":"Researcher","foaf:name":[{"@value":"Harumasa Yoshihara"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826618114","@type":"Researcher","foaf:name":[{"@value":"Eijirou Hayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617995","@type":"Researcher","foaf:name":[{"@value":"Yasuharu Imai"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617993","@type":"Researcher","foaf:name":[{"@value":"Michio Kato"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320826617986","@type":"Researcher","foaf:name":[{"@value":"Norio Hayashi"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13866346"},{"@type":"EISSN","@value":"1872034X"}],"prism:publicationName":[{"@value":"Hepatology Research"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2007-11-23","prism:volume":"38","prism:number":"5","prism:startingPage":"450","prism:endingPage":"456"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2007.00292.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1872-034X.2007.00292.x"}],"createdAt":"2007-11-27","modifiedAt":"2023-10-11","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Infectious%20Diseases","dc:title":"Infectious Diseases"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatology","dc:title":"Hepatology"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2007.00292.x"},{"@type":"OPENAIRE","@value":"doi_dedup___::26bd67ac5eff69c0f1e873b33f6e27ec"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_6vT3kF8cCWTwrnlwBIks292GZXE"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_6vT3kF8cCWTwrnlwBIks292GZXE"}]}